Benefits
Recurrent Strep Throat and Pharyngotonsillitis Prevention
Multiple controlled clinical trials in children and adults with histories of recurrent streptococcal pharyngitis show daily BLIS K12® reduces strep throat episodes dramatically. Treated children had about 90% fewer streptococcal episodes vs controls over the following year, with 80% fewer tonsillitis episodes and a 75% reduction in antibiotic prescriptions. A multicenter trial replicated the signal, and adult trials show similar protection — including in physically active populations.
Acute Otitis Media (Ear Infection) Reduction in Children
Ear infections often originate as throat or nasopharyngeal infections that ascend through the Eustachian tube. BLIS K12® has shown a 78% reduction in acute otitis media (AOM) episodes in children, and a dedicated pilot in children with secretory otitis media showed substantial reduction in AOM episodes plus positive outcomes on audiometry, tympanometry, and endoscopy. Especially relevant for children prone to recurrent ear infections.
Halitosis (Chronic Bad Breath) Reduction
Volatile sulfur compounds (VSCs) produced by anaerobic tongue bacteria are the microbial basis of chronic halitosis. In a placebo-controlled trial in adults with halitosis, 85% of the BLIS K12® group had VSC reductions exceeding 100 ppb in exhaled breath after one week vs 30% of placebo. A trial in 6-9 year olds replicated the signal — 78% with major-to-moderate improvement vs 20% in the brushing-only group, with high parental satisfaction.
Upper Respiratory Infection Prevention
Beyond strep specifically, BLIS K12® suppresses Haemophilus influenzae and Moraxella catarrhalis — common URI co-pathogens — and has shown reductions in viral pharyngitis, tracheitis, rhinitis, flu, and laryngitis in children. A randomized double-blind placebo-controlled trial in physically active young adults showed adherent supplementers had lower URI incidence than placebo. Particularly relevant for athletes, kindergarten children, and people in high-exposure settings.
Established Safety in Children and Adults
S. salivarius is a normal commensal that dominates the oral cavity of healthy individuals from the first hours of life, giving BLIS K12® a strong intrinsic safety rationale. A dedicated randomized double-blind placebo-controlled safety trial in healthy adults confirmed excellent tolerance. Across 30+ years of clinical research in children as young as 3, no consistent adverse events have been reported. GRAS-affirmed status in the US.
Reduced Antibiotic Use and Antibiotic Stewardship
Because BLIS K12® prevents the recurrent infections that drive antibiotic prescriptions, treated children recorded a 75% reduction in antibiotic courses vs controls. With antibiotic resistance now recognized as a major public health threat, oral probiotic prophylaxis offers a non-antimicrobial option for infection-prone children and adults — particularly meaningful for families dealing with year-after-year strep throat cycles.
Salivary Immunity Support
A randomized clinical trial showed BLIS K12® supplementation increased salivary secretory IgA — the primary mucosal antibody defending the upper airway — and improved oral biofilm composition. This explains how the probiotic supports broad respiratory immunity beyond just direct pathogen suppression, modulating cytokines (IL-6, IL-8, IL-10, IL-12, TNF-α) and increasing regulatory T cell frequency.
Mechanism of action
Salivaricin A2 and B Lantibiotic Production
BLIS K12® carries a 190-kilobase transmissible megaplasmid encoding two class-I lantibiotics — salivaricin A2 and salivaricin B. These ribosomally-synthesized post-translationally-modified peptides directly bind and disrupt cell-wall biosynthesis in Gram-positive pathogens, particularly Streptococcus pyogenes (Group A Strep). The lantibiotic activity is what distinguishes K12 from generic S. salivarius strains that lack these bacteriocin genes.
Oral Cavity Colonization and Niche Occupation
Unlike gut probiotics that transit through, BLIS K12® has been shown to establish persistent colonization on tongue and throat epithelium. By physically occupying the ecological niche pathogens need to attach to, the strain provides ongoing competitive exclusion — measurable as reduced pathogen recovery on throat swabs and persistent VSC reduction after supplementation stops in some users.
Broad-Spectrum Pathogen Suppression
Beyond S. pyogenes, the lantibiotics produced by K12 inhibit Streptococcus pneumoniae, Haemophilus influenzae non-typeable, and Moraxella catarrhalis — the dominant pathogens behind otitis media, sinusitis, and bronchitis. This polymicrobial coverage explains why K12 supplementation shows benefit across multiple upper respiratory conditions rather than just streptococcal infection.
Mucosal Immune Modulation
BLIS K12® colonization increases salivary secretory IgA — the primary mucosal antibody of the upper airway — and modulates cytokine production toward an anti-inflammatory profile (decreased IL-6 and IL-8, increased IL-10). A saliva trial published in Nutrients quantified the sIgA increase, providing a mechanistic bridge between strain colonization and the broad URI protection observed clinically.
Volatile Sulfur Compound Suppression
Halitosis is caused by anaerobic bacteria on the tongue producing hydrogen sulfide and methyl mercaptan from sulfur-containing amino acids. BLIS K12® inhibits these VSC-producing species while occupying their colonization sites. The foundational halitosis clinical trial documented an 85% VSC reduction exceeding 100 ppb in exhaled breath, directly linking the antimicrobial mechanism to the symptomatic halitosis outcome.
Regulatory T Cell Frequency Increase
Beyond direct antimicrobial action, BLIS K12® increases the frequency of regulatory T cells (Tregs) in peripheral blood. Tregs dampen overactive immune responses and reduce chronic inflammation — a mechanism that may contribute to the strain's emerging role in viral infection adjuvant trials, including reported reductions in COVID-19 mortality in hospitalized patients in a preliminary report.
Clinical trials
Foundational pediatric clinical trial. Children with a recent history of recurrent oral streptococcal pathology received either a daily slow-release oral tablet containing 5 billion CFU S. salivarius K12 for 90 days or no supplementation; followed for one year of strep episodes and antibiotic use.
82 children (45 treated, 37 control), with a recent diagnosis of recurrent pharyngeal streptococcal pathology.
Strep throat episodes per year dropped approximately 90% in the K12 group versus controls. Antibiotic prescriptions decreased 75%, tonsillitis episodes 80%, and acute otitis media episodes 78%. No adverse events. Established the prophylactic efficacy template that all later BLIS K12® respiratory trials build on.
Multicenter, open, nonrandomized, controlled clinical trial conducted across Milan (Italy) pediatric clinics. Children with recurrent pharyngeal streptococcal disease received daily BLIS K12® lozenges plus standard care, with 48 enrolled in the treated arm. Published in Drug, Healthcare and Patient Safety.
124 pediatric subjects (65 boys, 59 girls), with 48 children with recurrent pharyngeal streptococcal disease in the treated group.
Reduced occurrence of recurrent streptococcal pharyngeal disease, with benefits extending to non-streptococcal infections including tracheitis, viral pharyngitis, rhinitis, influenza, laryngitis, acute otitis media, and enteritis. Confirmed broad respiratory protection beyond streptococcal-specific effect, supporting the lantibiotic spectrum covering multiple URI pathogens.
6-month controlled clinical trial in children attending their first year of kindergarten (a high-exposure setting). Daily BLIS K12® administration vs control, with a 3-month follow-up after supplementation ended. Published in European Review for Medical and Pharmacological Sciences.
222 children (111 per group) in their first year of kindergarten, age 3.
Streptococcal pharyngo-tonsillitis incidence: 16% (treated) vs 48% (control). Scarlet fever: 9% vs 4%. Acute otitis media: 44% vs 80%. Benefits persisted into the 3-month follow-up period after supplementation stopped (15% vs 26% pharyngitis, 12% vs 36% AOM). All enrolled children completed the trial with no apparent side effects.
Randomized placebo-controlled clinical trial published in Journal of Applied Microbiology. Adults with diagnosed halitosis received BLIS K12® lozenges or matching placebo for 14 days, with exhaled VSC measured by Halimeter® and organoleptic breath scoring.
23 adults with diagnosed chronic halitosis (volatile sulfur compound baseline >100 ppb).
85% of the BLIS K12® group recorded VSC reductions exceeding 100 ppb in exhaled breath after one week, versus only 30% of placebo subjects. Effects persisted in approximately half of subjects for 2 weeks after discontinuation. The foundational halitosis trial establishing the VSC-suppression mechanism.
Randomized controlled clinical trial published in Oral Health & Preventive Dentistry, conducted at the Faculty of Dentistry, Tabriz University of Medical Sciences. Four-arm design comparing conventional oral hygiene (COH) alone, COH + tongue scraping (TS), COH + TS + chlorhexidine, and COH + TS + BLIS K12® over 3 months.
208 children (52 per group), age 6-9, with mild-to-strong oral malodor confirmed by experienced examiners.
The BLIS K12® arm (Group D) achieved major/moderate improvement on Organoleptic Test (OLT) scores in 78% of children, vs 20% (Group A, brushing alone), 43% (Group B, +tongue scraping), and 45% (Group C, +chlorhexidine). Parental satisfaction reached 91% for the K12 group; 96% of K12 children showed slight-to-major improvement. Confirmed the adult halitosis signal in pediatric population.
Pilot uncontrolled clinical trial published in International Journal of General Medicine. Children with diagnosed secretory otitis media (SOM) — persistent middle ear fluid lasting at least 2 months after acute otitis media — received daily BLIS K12® (1 billion CFU) for 90 days. Assessed by tone audiometry, tympanometry, endonasal endoscopy, otoscopy, and tonsillar examination.
22 children age 3-9 with recent acute otitis media and persistent middle ear fluid.
Substantial reduction in acute otitis media episodes during and after the 90-day intervention. Positive outcomes on all clinical measures (audiometry, tympanometry, endoscopy, otoscopy, tonsillar examination). Good safety profile with no adverse events. Limitations: uncontrolled design; signaled larger placebo-controlled trial was needed.
Randomized, double-blind, placebo-controlled clinical trial published in Microorganisms (2024). 4-month intervention with daily BLIS K12® (Bactoblis® formulation) vs placebo. URI incidence measured via the Jackson Scale and Wisconsin Upper Respiratory Symptom Survey (WURSS-11), with adherence closely tracked.
112 physically active young adults age 19-25.
Subjects with higher adherence to BLIS K12® showed lower URI incidence on both Jackson Scale and WURSS-11 vs placebo. Reinforces earlier pediatric findings in an athletic adult population where URI risk is elevated, and highlights adherence-dependent efficacy consistent with the niche-occupation mechanism.